Primary Objective:~- Evaluate tumor cell free (cf)DNA as a dynamic marker of response to immuno-oncology (IO) therapy~Exploratory Objective:~- Collect data on somatic mutations in cfDNA to gain insight into the biology of IO-responders and -non-responders
This study will assess whether DNA released by kidney cancer into the blood stream and urine of patients can be used to monitor tumor burden and tumor response to treatment in patients receiving immunotherapy